
Yoda Therapeutics Begins Phase 2 Trial for MSA Treatment
Yoda Therapeutics Inc. has dosed the first patient in its Phase 2 trial of YA-101 for Multiple System Atrophy (MSA), announced in a press release. MSA is a rare and rapidly progressing neurodegenerative disorder that severely impacts motor functions and autonomic systems.
YA-101, a novel chemical entity, aims to treat neurodegenerative diseases by inhibiting neuroinflammation and enhancing neural plasticity. The Phase 2 trial will assess the safety, tolerability, pharmacokinetics, and efficacy of YA-101 in MSA patients across multiple sites in the United States and Taiwan. This trial follows the successful completion of Phase 1 trials in Australia, which focused on safety and tolerability in healthy volunteers.
The trial is designed as a randomized, double-blind, placebo-controlled study, targeting MSA patients with walking ability, including those requiring assistance. Comprehensive assessments will be conducted through clinical symptoms, biomarkers, and imaging.
We hope you enjoyed this article.
Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.
Also, consider following us on social media:
More from: Healthcare & Life Sciences
Subscribe to Daily AI Brief
Daily report covering major AI developments and industry news, with both top stories and complete market updates
Whitepaper
Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation
The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.
Read more